Edition:
United Kingdom

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

0.42USD
17 Aug 2018
Change (% chg)

$-0.00 (-0.99%)
Prev Close
$0.42
Open
$0.43
Day's High
$0.43
Day's Low
$0.42
Volume
111,280
Avg. Vol
652,550
52-wk High
$3.26
52-wk Low
$0.41

Chart for

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $405.56
Shares Outstanding(Mil.): 128.34
Dividend: --
Yield (%): --

Financials

  CLDX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.10 -- --
ROI: -43.88 1.78 14.61
ROE: -53.51 3.28 16.33

BRIEF-Celldex Therapeutics Reports Q1 Loss Per Share $0.84

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 RESULTS

10 May 2018

BRIEF-Celldex Therapeutics Approves Workforce Reduction

* CELLDEX THERAPEUTICS INC - APPROVED A REDUCTION IN WORKFORCE TO REDUCE OPERATING COSTS AND BETTER ALIGN ITS WORKFORCE WITH NEEDS OF ITS BUSINESS

24 Apr 2018

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

16 Apr 2018

BRIEF-Celldex Therapeutics Reports Q4 Loss Per Share $0.03

* CELLDEX PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 RESULTS

07 Mar 2018

Earnings vs. Estimates